Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete | ||
Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Retevmo | selpercatinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyndaqel | tafamidis | Transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete |